GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Surmodics Inc (NAS:SRDX) » Definitions » Equity-to-Asset

Surmodics (Surmodics) Equity-to-Asset

: 0.68 (As of Dec. 2023)
View and export this data going back to 1998. Start your Free Trial

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Surmodics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $122.2 Mil. Surmodics's Total Assets for the quarter that ended in Dec. 2023 was $180.2 Mil. Therefore, Surmodics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.68.

The historical rank and industry rank for Surmodics's Equity-to-Asset or its related term are showing as below:

SRDX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.6   Med: 0.8   Max: 0.95
Current: 0.68

During the past 13 years, the highest Equity to Asset Ratio of Surmodics was 0.95. The lowest was 0.60. And the median was 0.80.

SRDX's Equity-to-Asset is ranked better than
54.25% of 870 companies
in the Medical Devices & Instruments industry
Industry Median: 0.65 vs SRDX: 0.68

Surmodics Equity-to-Asset Historical Data

The historical data trend for Surmodics's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Surmodics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Equity-to-Asset
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.78 0.72 0.68 0.65

Surmodics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.63 0.62 0.60 0.65 0.68

Competitive Comparison

For the Medical Devices subindustry, Surmodics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Surmodics Equity-to-Asset Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Surmodics's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Surmodics's Equity-to-Asset falls into.



Surmodics Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Surmodics's Equity to Asset Ratio for the fiscal year that ended in Sep. 2023 is calculated as

Equity to Asset (A: Sep. 2023 )=Total Stockholders Equity/Total Assets
=119.91/185.733
=0.65

Surmodics's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=122.15/180.24
=0.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Surmodics  (NAS:SRDX) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Surmodics Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Surmodics's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Surmodics (Surmodics) Business Description

Traded in Other Exchanges
Address
9924 West 74th Street, Eden Prairie, MN, USA, 55344
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using its technology to provide solutions to difficult medical devices and diagnostic challenges. It has two reportable segments: Medical device unit; Manufacture of performance coatings, including surface modification coating technologies and the Vitro diagnostics unit; Manufacture of chemical and biological components used in in vitro diagnostic immunoassay and molecular tests within the diagnostic and biomedical research markets. Surmodics derives majority of its revenue from the Medical Device segment.
Executives
Jose H Bedoya director
David Dantzker other: See Explanation of Responses 80 CUTTERMILL ROAD STE 311, GREAT NECK NY 11021
Kalich Ronald B Sr director
Gary R Maharaj director, officer: President & CEO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Joseph J. Stich officer: VP, Corp Dev & Strat Planning 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Charles W Olson officer: General Manager
John D. Manders officer: Corporate Controller 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gordon S. Weber officer: Sr. VP of Legal, GC and Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Nusrath Sultana officer: VP, Clinical Affairs 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Lisa Wipperman Heine director 1244 76TH STREET WEST, INVER GROVE HEIGHTS MN 55077
Teri Woodwick Sides officer: Senior VP and CMO 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Gregg S Sutton officer: VP of Research and Development 6464 SYCAMORE COURT NORTH, MINNEAPOLIS MN 55369
Susan E Knight director 9154 BRECKENRIDGE LANE, EDEN PRAIRIE MN 55437
Bryan K Phillips officer: Dep. Gen. Counsel & Corp. Sec. 9924 WEST 74TH STREET, EDEN PRAIRIE MN 55344
Timothy J. Arens officer: General Manager - IVD 9924 WEST 74TH STREET, EDEN PRAIRIE X1 55344

Surmodics (Surmodics) Headlines